Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

NCT05255666 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05255666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05255666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2023
Completion date
January 31, 2030
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, triple negative breast cancer